tradingkey.logo

Sight Sciences Inc

SGHT
View Detailed Chart
8.440USD
0.000
Close 12/23, 16:00ETQuotes delayed by 15 min
442.88MMarket Cap
LossP/E TTM

Sight Sciences Inc

8.440
0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

+1.56%

1 Month

+16.25%

6 Months

+107.88%

Year to Date

+131.87%

1 Year

+136.41%

View Detailed Chart

TradingKey Stock Score of Sight Sciences Inc

Currency: USD Updated: 2025-12-22

Key Insights

Sight Sciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 91/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.42.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sight Sciences Inc's Score

Industry at a Glance

Industry Ranking
91 / 208
Overall Ranking
216 / 4578
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
6.417
Target Price
-24.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sight Sciences Inc Highlights

StrengthsRisks
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.87M.
Undervalued
The company’s latest PE is -9.44, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.78M shares, decreasing 27.62% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.89K shares of this stock.

Sight Sciences Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Sight Sciences Inc Info

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Ticker SymbolSGHT
CompanySight Sciences Inc
CEOBadawi (Paul)
Websitehttps://www.sightsciences.com/

FAQs

What is the current price of Sight Sciences Inc (SGHT)?

The current price of Sight Sciences Inc (SGHT) is 8.440.

What is the symbol of Sight Sciences Inc?

The ticker symbol of Sight Sciences Inc is SGHT.

What is the 52-week high of Sight Sciences Inc?

The 52-week high of Sight Sciences Inc is 8.800.

What is the 52-week low of Sight Sciences Inc?

The 52-week low of Sight Sciences Inc is 2.030.

What is the market capitalization of Sight Sciences Inc?

The market capitalization of Sight Sciences Inc is 442.88M.

What is the net income of Sight Sciences Inc?

The net income of Sight Sciences Inc is -51.51M.

Is Sight Sciences Inc (SGHT) currently rated as Buy, Hold, or Sell?

According to analysts, Sight Sciences Inc (SGHT) has an overall rating of Buy, with a price target of 6.417.

What is the Earnings Per Share (EPS TTM) of Sight Sciences Inc (SGHT)?

The Earnings Per Share (EPS TTM) of Sight Sciences Inc (SGHT) is -0.894.
KeyAI